Last reviewed · How we verify
CKD-393
At a glance
| Generic name | CKD-393 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 (PHASE1)
- Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393 (PHASE1)
- A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions (PHASE1)
- A Study to Investigate the PK and Safety of CKD-393 (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects (PHASE1)
- Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 (PHASE1)
- A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-393 CI brief — competitive landscape report
- CKD-393 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI